RECRUITING

Cognition and Imaging With Tigertriever

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The objective of the COGNITIVE Study is to evaluate whether successful reperfusion with Tigertriever is associated with cognitive benefit.

Official Title

COGNITIVE Study- Cognition and Imaging With Tigertriever

Quick Facts

Study Start:2024-10-28

Study Completion:2026-11

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05531461

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as indicated per the approved IFU. 2. Tigertriever was used as the first line treatment in the target vessel. 3. A signed informed consent. 4. Age 18-75 years (inclusive). 5. No known significant pre-stroke disability (pre-stroke mRS 0 or 1).	1. Use of any other IA recanalization device prior to the Tigertriever in the target vessel, including aspiration catheter. 2. Evidence of acute brain hemorrhage on CT and/or MRI at admission. 3. Prior hemorrhage, stroke, thrombolysis, and/or endovascular therapy in the last 3 months. 4. Probable cerebral amyloid angiopathy. 5. Pre-stroke diagnosed dementia and/or prescribed cholinesterase inhibitors. 6. Pre-stroke diagnosed and/or currently treated major depression. 7. Pre-stroke learning or intellectual disability. 8. Anticipated inability to obtain 6-month follow-up assessments.

Inclusion Criteria

Exclusion Criteria

1. Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as indicated per the approved IFU.
2. Tigertriever was used as the first line treatment in the target vessel.
3. A signed informed consent.
4. Age 18-75 years (inclusive).
5. No known significant pre-stroke disability (pre-stroke mRS 0 or 1).

1. Use of any other IA recanalization device prior to the Tigertriever in the target vessel, including aspiration catheter.
2. Evidence of acute brain hemorrhage on CT and/or MRI at admission.
3. Prior hemorrhage, stroke, thrombolysis, and/or endovascular therapy in the last 3 months.
4. Probable cerebral amyloid angiopathy.
5. Pre-stroke diagnosed dementia and/or prescribed cholinesterase inhibitors.
6. Pre-stroke diagnosed and/or currently treated major depression.
7. Pre-stroke learning or intellectual disability.
8. Anticipated inability to obtain 6-month follow-up assessments.

Contacts and Locations

Study Contact

Walid Haddad, Dr.

CONTACT

+972 72 2503331

walid@rapid-medical.com

Study Locations (Sites)

University of California

Los Angeles, California, 90095

United States

Westchester Medical Center

New York, New York, 10595

United States

Collaborators and Investigators

Sponsor: Rapid Medical

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-10-28

Study Completion Date2026-11

Study Record Updates

Study Start Date2024-10-28

Study Completion Date2026-11

Terms related to this study

Additional Relevant MeSH Terms

Stroke